S&P 500   3,156.58 (+0.91%)
DOW   27,343.27 (+0.97%)
QQQ   218.19 (+1.31%)
AAPL   291.36 (+1.14%)
FB   198.65 (+0.96%)
AMZN   1,993.44 (+1.05%)
NVDA   268.00 (+2.27%)
MU   53.54 (+2.76%)
TSLA   788.01 (-1.49%)
AMD   48.34 (+1.62%)
T   37.16 (-0.54%)
ACB   1.50 (-0.66%)
PRI   122.72 (+1.07%)
S&P 500   3,156.58 (+0.91%)
DOW   27,343.27 (+0.97%)
QQQ   218.19 (+1.31%)
AAPL   291.36 (+1.14%)
FB   198.65 (+0.96%)
AMZN   1,993.44 (+1.05%)
NVDA   268.00 (+2.27%)
MU   53.54 (+2.76%)
TSLA   788.01 (-1.49%)
AMD   48.34 (+1.62%)
T   37.16 (-0.54%)
ACB   1.50 (-0.66%)
PRI   122.72 (+1.07%)
S&P 500   3,156.58 (+0.91%)
DOW   27,343.27 (+0.97%)
QQQ   218.19 (+1.31%)
AAPL   291.36 (+1.14%)
FB   198.65 (+0.96%)
AMZN   1,993.44 (+1.05%)
NVDA   268.00 (+2.27%)
MU   53.54 (+2.76%)
TSLA   788.01 (-1.49%)
AMD   48.34 (+1.62%)
T   37.16 (-0.54%)
ACB   1.50 (-0.66%)
PRI   122.72 (+1.07%)
S&P 500   3,156.58 (+0.91%)
DOW   27,343.27 (+0.97%)
QQQ   218.19 (+1.31%)
AAPL   291.36 (+1.14%)
FB   198.65 (+0.96%)
AMZN   1,993.44 (+1.05%)
NVDA   268.00 (+2.27%)
MU   53.54 (+2.76%)
TSLA   788.01 (-1.49%)
AMD   48.34 (+1.62%)
T   37.16 (-0.54%)
ACB   1.50 (-0.66%)
PRI   122.72 (+1.07%)
Log in

NYSE:CBM - Cambrex Stock Price, Forecast & News

$59.99
0.00 (0.00 %)
(As of 01/27/2020)
Today's Range
$59.99
Now: $59.99
$59.99
50-Day Range
$59.99
MA: $59.99
$59.99
52-Week Range
$33.80
Now: $59.99
$60.29
VolumeN/A
Average Volume218,726 shs
Market Capitalization$2.02 billion
P/E Ratio21.66
Dividend YieldN/A
Beta2.14
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP13201110
Phone201-804-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$532.09 million
Cash Flow$3.91 per share
Book Value$19.48 per share

Profitability

Net Income$92.41 million

Miscellaneous

Employees1,732
Market Cap$2.02 billion
Next Earnings DateN/A
OptionableOptionable

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.


Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) issued its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to the consensus estimate of $132.78 million. Cambrex had a net margin of 5.96% and a return on equity of 5.38%. Cambrex's revenue was up 13.0% on a year-over-year basis. During the same period last year, the business posted $0.76 EPS. View Cambrex's Earnings History.

What price target have analysts set for CBM?

4 analysts have issued 12-month price targets for Cambrex's stock. Their forecasts range from $44.00 to $60.00. On average, they expect Cambrex's stock price to reach $54.75 in the next year. This suggests that the stock has a possible downside of 8.7%. View Analyst Price Targets for Cambrex.

What is the consensus analysts' recommendation for Cambrex?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.

Has Cambrex been receiving favorable news coverage?

Media stories about CBM stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cambrex earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Cambrex.

Who are some of Cambrex's key competitors?

What other stocks do shareholders of Cambrex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), NVIDIA (NVDA), Intel (INTC), Under Armour (UAA), Broadcom (AVGO) and Juno Therapeutics (JUNO).

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. James G. Farrell, VP & Corp. Controller (Age 52)

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $59.99.

How big of a company is Cambrex?

Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.

What is Cambrex's official website?

The official website for Cambrex is http://www.cambrex.com/.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (NYSE CBM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  294 (Vote Underperform)
Total Votes:  595
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel